Variable name;level;Overall;Curie Paris;Curie St Cloud;p;test
;n;1357;818;538;;
Age;[0 -30);95;74 (77.9);21 (22.1);0.003;
;[30 -35);246;145 (58.9);101 (41.1);;
;[35 -40);460;266 (57.8);194 (42.2);;
;40+;554;332 (59.9);222 (40.1);;
Number of children;0;373;254 (68.3);118 (31.7);<0.001;
;1;279;171 (61.3);108 (38.7);;
;More than 1;705;393 (55.7);312 (44.3);;
BMI;<18.5;79;51 (64.6);28 (35.4);0.158;
;25-29.9;257;165 (64.5);91 (35.5);;
;>=30;107;60 (56.1);47 (43.9);;
;18.5-24.9;807;541 (67);266 (33);;
Hereditary predisposition;No;547;347 (63.6);199 (36.4);0.033;
;Yes;140;103 (73.6);37 (26.4);;
Inflammatory BC;No;1338;808 (60.4);530 (39.6);0.862;
;Yes;18;10 (55.6);8 (44.4);;
Clinical Tumor size (mm);;30.3 (21.7);30.6 (21.9);29.8 (21.4);0.503;
Clinical N stage (TNM);N0;854;479 (56.1);375 (43.9);<0.001;
;N1;482;331 (68.7);151 (31.3);;
;N2;7;3 (42.9);4 (57.1);;
;N3;3;2 (66.7);1 (33.3);;
SBR grade;Grade I;58;19 (32.8);39 (67.2);<0.001;
;Grade II;528;310 (58.7);218 (41.3);;
;Grade III;760;483 (63.6);277 (36.4);;
Histological type;Lobular;54;37 (68.5);17 (31.5);0.129;
;NST;1265;764 (60.4);501 (39.6);;
;Others;36;17 (47.2);19 (52.8);;
Neoajuvant chemotherapy;No;744;421 (56.6);323 (43.4);0.002;
;Yes;612;397 (64.9);215 (35.1);;
Chemotherapy setting;Adjuvant;744;421 (56.6);323 (43.4);0.003;
;Chemotherapy without surgery;1;0 (0);1 (100);;
;NAC;611;397 (65);214 (35);;
Fertility preservation discussion;No;909;531 (58.4);378 (41.6);0.047;
;Yes;447;287 (64.2);160 (35.8);;
